NCT00769522 - FCR or BR in Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia | Biotech Hunter

Enrollment

564

Participants

Timeline

Start Date

October 2, 2008

Primary Completion Date

July 31, 2011

Study Completion Date

January 31, 2018

Conditions

Chronic Lymphocytic Leukemia

Interventions

BIOLOGICAL

Rituximab

"cycle 1: 375 mg/m² i.v., day 0, q28d~cycle 2-6: 500 mg/m² i.v., day 1, q28d"

DRUG

Bendamustine

cycle 1-6: 90mg/m² i.v., day 1-2, q28d

DRUG

Cyclophosphamide

cycle 1-6: 250 mg/m² i.v., days 1-3, q28d

DRUG

Fludarabine

cycle 1-6: 25 mg/m² i.v., days 1-3, q28d

Trial Locations (1)

Medizinische Universitaetsklinik I at the University of Cologne, Cologne